Ayala Pharmaceuticals Inc. (ADXS)
OTCMKTS: ADXS · Delayed Price · USD
0.150
0.00 (0.00%)
Jul 19, 2024, 4:00 PM EDT - Market open
Ayala Pharmaceuticals Employees
As of December 31, 2023, Ayala Pharmaceuticals had 21 total employees, including 20 full-time and 1 part-time employees.
Employees
21
Change
n/a
Growth
n/a
Revenue / Employee
$619
Profits / Employee
-$2,289,143
Market Cap
6.40M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 21 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher | 122,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
| Danaher | 63,000 |
ADXS News
- 2 months ago - Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations - GlobeNewsWire
- 4 months ago - Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome - GlobeNewsWire
- 5 months ago - Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors - Business Wire
- 5 months ago - Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals - Business Wire
- 9 months ago - Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 - GlobeNewsWire
- 9 months ago - Ayala Pharmaceuticals Announces Closing of Merger with Biosight - GlobeNewsWire
- 1 year ago - Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023 - GlobeNewsWire